BIAL focuses its activity in Mozambique on the commercialisation of medicines
BIAL strengthened the focus of its activity in Mozambique on the commercialisation of medicines, as is the case in the international markets where it is present, having disposed of its import and distribution operation for pharmaceutical specialities with the sale of the company Medimport to CFAO Healthcare.
Established in 1998, Medimport acted as a medicine distributor in the Mozambican market, an activity that BIAL exclusively held in this country. CFAO Healthcare is one of the leading pharmaceutical logistics companies primarily focused on Africa. The company employs over 3,800 people and operates in more than 28 countries across Africa.
Considering BIAL’s strategic focus on Research and Development in the areas of neurosciences and rare diseases, the Group decided to dispose of an operation that was disconnected from its core business.
The disposal of its import and distribution operation, now finalized and approved by the authorities, will not affect the commercialisation of BIAL’s medicines in the Mozambican market. BIAL has full confidence in CFAO Healthcare to continue ensuring the availability of BIAL’s products to patients and to provide the highest medical service to healthcare professionals
